FFEA Stock Overview
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Faes Farma, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.25 |
| 52 Week High | €3.41 |
| 52 Week Low | €2.85 |
| Beta | 0.49 |
| 1 Month Change | 4.68% |
| 3 Month Change | 5.70% |
| 1 Year Change | 6.74% |
| 3 Year Change | -7.44% |
| 5 Year Change | -19.58% |
| Change since IPO | -59.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| FFEA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 4.8% | 3.2% | 1.7% |
| 1Y | 6.7% | -28.2% | 2.3% |
Return vs Industry: FFEA exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: FFEA exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| FFEA volatility | |
|---|---|
| FFEA Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FFEA has not had significant price volatility in the past 3 months.
Volatility Over Time: FFEA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 1,748 | n/a | faesfarma.com |
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu.
Faes Farma, S.A. Fundamentals Summary
| FFEA fundamental statistics | |
|---|---|
| Market cap | €1.02b |
| Earnings (TTM) | €91.90m |
| Revenue (TTM) | €473.09m |
11.1x
P/E Ratio2.2x
P/S RatioIs FFEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FFEA income statement (TTM) | |
|---|---|
| Revenue | €473.09m |
| Cost of Revenue | €160.78m |
| Gross Profit | €312.31m |
| Other Expenses | €220.41m |
| Earnings | €91.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.30 |
| Gross Margin | 66.01% |
| Net Profit Margin | 19.43% |
| Debt/Equity Ratio | 3.2% |
How did FFEA perform over the long term?
See historical performance and comparison